Risk factors
Biodesix (BDSX) risk factors
Item 1A of every Biodesix Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors108 risks9 new10 dropped17 reworded
Biodesix added numerous risks regarding FDA regulation of laboratory-developed tests, artificial intelligence adoption, patent protection, and maintaining Nasdaq minimum bid price compliance following a reverse stock split.
Filed Feb 26, 2026 - FY2024 10-K risk factors109 risks
Biodesix faces continuous operating losses with an accumulated deficit of $462.5 million as of December 31, 2024. Revenue depends heavily on Medicare reimbursement and biopharmaceutical collaborations. The company relies on single-source suppliers like Bio-Rad for its GeneStrat test.
Filed Mar 03, 2025